NO20075662L - Roflumilast for behandlingen av pulmonal hypertensjon - Google Patents

Roflumilast for behandlingen av pulmonal hypertensjon

Info

Publication number
NO20075662L
NO20075662L NO20075662A NO20075662A NO20075662L NO 20075662 L NO20075662 L NO 20075662L NO 20075662 A NO20075662 A NO 20075662A NO 20075662 A NO20075662 A NO 20075662A NO 20075662 L NO20075662 L NO 20075662L
Authority
NO
Norway
Prior art keywords
roflumilast
treatment
pulmonary hypertension
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO20075662A
Other languages
English (en)
Inventor
Armin Hatzelmann
Christian Schudt
Rolf Beume
Degenhard Marx
Hermann Tenor
Saadia Eddahibi
Serge Adnot
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of NO20075662L publication Critical patent/NO20075662L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen vedrører anvendelsen av Roflumilast, Roflumilast-N-oksid eller et farmasøytisk akseptabelt salt av den ene eller den andre for behandlingen av pulmonal hypertensjon. Oppfinnelsen vedrører i tillegg anvendelsen av Roflumilast, Roflumilast-N-oksid eller et farmasøytisk akseptabelt salt av den ene eller den andre i kombinasjon med en PDE5-inhibitor eller et farmasøytisk akseptabelt salt derav for behandlingen av pulmonal hypertensjon. ?? ?? ?? ?? - 1 -
NO20075662A 2005-04-19 2007-11-07 Roflumilast for behandlingen av pulmonal hypertensjon NO20075662L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05103147 2005-04-19
PCT/EP2006/061557 WO2006111495A1 (en) 2005-04-19 2006-04-12 Roflumilast for the treatment of pulmonary hypertension

Publications (1)

Publication Number Publication Date
NO20075662L true NO20075662L (no) 2007-11-07

Family

ID=34939388

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075662A NO20075662L (no) 2005-04-19 2007-11-07 Roflumilast for behandlingen av pulmonal hypertensjon

Country Status (24)

Country Link
US (1) US8648100B2 (no)
EP (2) EP2366393B1 (no)
JP (2) JP2008536888A (no)
KR (1) KR101358479B1 (no)
CN (2) CN102614176A (no)
AU (1) AU2006237300B2 (no)
BR (1) BRPI0610498A2 (no)
CA (1) CA2604295C (no)
CY (1) CY1114468T1 (no)
DK (1) DK2366393T3 (no)
EA (1) EA016037B1 (no)
ES (1) ES2433661T3 (no)
HR (1) HRP20130982T1 (no)
IL (2) IL186538A0 (no)
ME (1) ME01609B (no)
MX (1) MX2007012711A (no)
NO (1) NO20075662L (no)
NZ (1) NZ561746A (no)
PL (1) PL2366393T3 (no)
PT (1) PT2366393E (no)
RS (1) RS52944B (no)
SI (1) SI2366393T1 (no)
WO (1) WO2006111495A1 (no)
ZA (1) ZA200707930B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009013286A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Organic compounds
WO2009115235A1 (en) * 2008-03-20 2009-09-24 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of pulmonary hypertension
EP2948148B1 (en) 2013-01-28 2020-07-29 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN107038965A (zh) * 2017-05-05 2017-08-11 深圳浩翔光电技术有限公司 Led显示装置、成型模组、及其生产工艺
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
KR20190005708A (ko) * 2017-07-05 2019-01-16 이화여자대학교 산학협력단 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물
BR112022015104A2 (pt) * 2020-01-31 2022-09-27 Arcutis Biotherapeutics Inc Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição
CN115969847A (zh) * 2023-02-03 2023-04-18 华中科技大学 罗氟司特在制备治疗心力衰竭的药物中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB371800A (en) 1929-10-21 1932-04-28 Willem Zaadnoordijk A process of filtering gases and fogs
GB343664A (en) 1929-12-27 1931-02-26 William Duncan Grant Subaquatic rock drilling devices
GB357903A (en) 1931-01-05 1931-10-01 Oskar Rosenfelder Improvements in catamenial appliances and infants' diapers
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
ES2176252T3 (es) 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
US5728705A (en) 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
AU6823098A (en) 1997-02-28 1998-09-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
EP0977756A1 (en) 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
FR2762841B1 (fr) * 1997-04-30 1999-07-02 Jouveinal Inst Rech Diazepino-indolones inhibitrices de phosphodiesterases iv
US6362178B1 (en) 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
HRP20000712A2 (en) 1998-04-20 2001-06-30 Pfizer PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
DE19819023A1 (de) 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
CA2368023A1 (en) 1999-03-22 2000-09-28 Guixue Yu Fused pyridopyridazine inhibitors of cgmp phosphodiesterase
EP1219609B1 (en) 1999-09-16 2007-04-04 Tanabe Seiyaku Co., Ltd. Aromatic nitrogenous six-membered ring compounds
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ATE305467T1 (de) * 2001-01-31 2005-10-15 Pfizer Prod Inc Als inhibitoren von pde4-isozymen geeignete etherderivate
WO2002060898A1 (en) * 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
US6973229B1 (en) * 2001-02-28 2005-12-06 Lambda Opticalsystems Corporation Node architecture for modularized and reconfigurable optical networks, and methods and apparatus therefor
DE10135815A1 (de) 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
HUP0401747A3 (en) * 2001-11-05 2005-06-28 Merck Patent Gmbh Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
EP1505972A2 (en) * 2002-05-16 2005-02-16 Pharmacia Corporation A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
WO2004072079A1 (en) 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
WO2004096274A1 (ja) 2003-03-31 2004-11-11 Kyowa Hakko Kogyo Co., Ltd. 気道内投与剤
EA012279B1 (ru) * 2003-05-22 2009-08-28 Никомед Гмбх Композиция, включающая ингибитор pde4 и ингибитор pde5
WO2004105751A1 (en) * 2003-05-28 2004-12-09 Glaxo Group Limited Traitement of cardiovascular pathology
US7132435B2 (en) * 2003-07-25 2006-11-07 Pfizer Inc. Compounds
GB0317498D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Compounds
US7153870B2 (en) * 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
CA2536293A1 (en) 2003-08-22 2005-03-03 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating copd and pulmonary hypertension
US20050239867A1 (en) 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension

Also Published As

Publication number Publication date
CN101163476A (zh) 2008-04-16
CA2604295C (en) 2014-10-07
MX2007012711A (es) 2008-01-11
EP2366393A2 (en) 2011-09-21
RS52944B (sr) 2014-02-28
US8648100B2 (en) 2014-02-11
JP2008536888A (ja) 2008-09-11
NZ561746A (en) 2011-09-30
KR101358479B1 (ko) 2014-02-06
ZA200707930B (en) 2008-05-28
IL218745A0 (en) 2012-05-31
AU2006237300B2 (en) 2011-10-13
US20090215836A1 (en) 2009-08-27
EP2366393A3 (en) 2011-09-28
JP2013237683A (ja) 2013-11-28
HRP20130982T1 (hr) 2013-11-22
WO2006111495A1 (en) 2006-10-26
SI2366393T1 (sl) 2013-12-31
EP1874309A1 (en) 2008-01-09
PL2366393T3 (pl) 2014-01-31
EP2366393B1 (en) 2013-08-07
CN102614176A (zh) 2012-08-01
AU2006237300A1 (en) 2006-10-26
IL186538A0 (en) 2008-06-05
PT2366393E (pt) 2013-10-04
ES2433661T3 (es) 2013-12-12
EA016037B1 (ru) 2012-01-30
ME01609B (me) 2014-09-20
CY1114468T1 (el) 2017-01-25
KR20080002950A (ko) 2008-01-04
CA2604295A1 (en) 2006-10-26
EA200702201A1 (ru) 2008-04-28
DK2366393T3 (da) 2013-10-21
BRPI0610498A2 (pt) 2010-06-22

Similar Documents

Publication Publication Date Title
NO20075662L (no) Roflumilast for behandlingen av pulmonal hypertensjon
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20081592L (no) Dipeptidylpeptidaseinhibitorer for behandling av diabetes
EA201070786A1 (ru) Бензофуропиримидиноны
NO20071095L (no) Hittil ukjente tiofenderivater
ATE483707T1 (de) 2-cyclopropylthiazolderivate
EA200870409A1 (ru) Антагонисты киназы pi3
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
UY29246A1 (es) Nuevos compuestos
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
NO20081569L (no) Administrasjon av dipeptidylpeptildaseinhibitorer
NO20082793L (no) Nye tiofenderivater
EA201070127A1 (ru) Способы лечения легочной гипертензии, родственных заболеваний и нарушений и композиции для их осуществления
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
NO20092146L (no) Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en 5-HT1A-agonist, i behandlingen av seksuell dysfunksjon
CY1114735T1 (el) Θεραπευτικες συνθεσεις οι οποιες περιεχουν εναν ειδικο ανταγωνιστη του υποδοχεα της ενδοθηλινης και εναν αναστολεα της pde5
HRP20090074T3 (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
EA200901034A1 (ru) 6-БЕНЗИЛ-2,3,4,7-ТЕТРАГИДРОИНДОЛО [2,3-c]ХИНОЛИНЫ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФДЭ5 (ФОСФОДИЭСТЕРАЗЫ 5)

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

FC2A Withdrawal, rejection or dismissal of laid open patent application